Abstract
Cardiovascular disease is the leading causes of death. However, the complications can be treated with heparin and heparinoids, such as heparin pentasaccharide Fondaparinux, dermatan sulfate, and PSS made from alginate extracted from brown seaweeds by chemical sulfation. Alginate is composed of a linear backbone of polymannuronate (PM), polyguluronate (PG), and alternate residues of mannuronic acid and guluronic acid. It is unknown if heparin and sulfated PG (PGS)/PM (PMS) have the same or different anticoagulant molecular targets. In the current study, the anticoagulant activities of PGS, PMS, and their oligosaccharides were directly compared to that of heparin, Fondaparinux, and dermatan sulfate by the activated partial thrombinplastin time (aPTT) assay using normal, antithrombin III (ATIII)-deficient, heparin co-factor II (HCII)-deficient, and ATIII- and HCII-double deficient human plasmas. Our results showed that PGS, PMS, and their oligosaccharides had better anticoagulant activity than that of Fondaparinux in all four human plasmas tested. As expected, heparin was the best anticoagulant in normal plasma. Moreover, PGS, PGS6, PGS12, PGS25, PMS6, PMS12, and PMS25 were better anticoagulants than dermatan sulfate in HCII-deficient plasma. Most strikingly, PGS, PGS12, PGS25, PMS6, PMS12, and PMS25 were better anticoagulants than that of heparin in ATIII- and HCII-double deficient human plasma. The results revealed for the first time that sulfated alginate had ATIII- and HCII-independent anticoagulant activities. Therefore, developing PGS and PMS-based anticoagulants might require to discover their major molecular targets and to develop target-specific anticoagulant assays.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amare, A. T., Shrime, M., and Newton, C., 2015. Global, regional, and national age-sex specific all-cause and causespecific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. The Lancet, 385 (9963): 117–171.
Bartnik, M., Norhammar, A., and Ryden, L., 2007. Hyperglycaemia and cardiovascular disease. Journal of Internal Medicine, 262 (2): 145–156.
Bjork, I., and Lindahl, U., 1982. Mechanism of the anticoagulant action of heparin. Molecular and Cellular Biochemistry, 48 (3): 161–182.
China Heparin Industry Report. 2015-2018. http://www.researchinchina. com/Htmls/Report/2015/10204.html.
Colman, R. W., 2006. Hemostasis and Thrombosis. Lippincott Williams & Wilkins, 271-283.
Dun, Y. L., Zhou, X. L., Guan, H. S., Yu, G. L., Li, C. X., Hu, T., Zhao, X., Cheng, X. L., He, X. X., and Hao, J. J., 2015. Low molecular weight guluronate prevents TNF-alpha-induced oxidative damage and mitochondrial dysfunction in C2C12 skeletal muscle cells. Food & Function, 6 (9): 3056–3064.
Duvall, W. L., 2006. Antithrombotic therapy. Current Molecular Medicine, 6 (5): 603–619.
Grand’Maison, A., Charest, A. F., and Geerts, W. H., 2005. Anticoagulant use in patients with chronic renal impairment. American Journal of Cardiovascular Drugs, 5 (5): 291–305.
Gresele, P., Busti, C., and Paganelli, G., 2012. Heparin in the prophylaxis and treatment of venous thromboembolism and other thrombotic diseases. Handbook of Experimental Pharmacology, 207: 179–209.
Halldorsdottir, A. M., Zhang, L., and Tollefsen, D. M., 2006. N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate. Glycobiology, 16 (8): 693–701.
Korte, W., Clarke, S., and Lefkowitz, J. B., 2000. Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. American Journal of Clinical Pathology, 113 (1): 123–127.
Langdell, R. D., Wagner, R. H., and Brinkhous, K. M., 1953. Effect of antihemophilic factor on one-stage clotting tests: A presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. Journal of Laboratory and Clinical Medicine, 41 (4): 637–647.
Lawrence, R., Lu, H., Rosenberg, R. D., Esko, J. D., and Zhang, L., 2008. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nature Methods, 5 (4): 291–292.
Liang, G., and Bowen, J. P., 2016. Development of trypsin-like serine protease inhibitors as therapeutic agents: Opportunities, challenges, and their unique structure-based rationales. Current Topics in Medicinal Chemistry, 16 (13): 1506–1529.
Lu, H., McDowell, L. M., Studelska, D. R., and Zhang, L., 2010. Glycosaminoglycans in human and bovine serum: Detection of twenty-four heparan sulfate and chondroitin sulfate motifs including a novel sialic acid-modified chondroitin sulfate linkage hexasaccharide. Glycobiology Insights, 2010 (2): 13–28.
Mabeau, S., and Kloareg, B., 1987. Isolation and analysis of the cell walls of brown algae: Fucus spiralis, f. ceranoides, f. vesiculosus, f. serratus, Bifurcaria bifurcata and Laminaria digitata. Journal of Experimental Botany, 38 (9): 1573–1580.
McDowell, L. M., Frazier, B. A., Studelska, D. R., Giljum, K., Chen, J., Liu, J., Yu, K., Ornitz, D. M., and Zhang, L., 2006. Inhibition or activation of Apert syndrome FGFR2 (S252W) signaling by specific glycosaminoglycans. Journal of Biological Chemistry, 281 (11): 6924–6930.
Mousa, S. A., 2006. Role of current and emerging antithrombotics in thrombosis and cancer. Drugs of Today, 42 (5): 331–350.
Peters, R. J., Joyner, C., Bassand, J. P., Afzal, R., Chrolavicius, S., Mehta, S. R., Oldgren, J., Wallentin, L., Budaj, A., Fox, K. A., Yusuf, S., and Investigators, O., 2008. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: A subgroup analysis of the OASIS-6 trial. European Heart Journal, 29 (3): 324–331.
Qian, Y., Pan, J., Zhou, X. D., Hourcade, D. E., Liszewski, M. K., Atkinson, J. P., Hong, L., and Zhang L. J., 2010. Oversulfated heparin by-products induce thrombin generation in human plasmas through contact system activation. Clinical and Applied Thrombosis/Hemostasis, 16 (3): 244–250.
Trailokya, A., Dhall, A., and Kumbla, D. K., 2015. Fondaparinux in acute coronary syndromes. Journal of the Association of Physicians of India, 63 (7): 83–87.
Wu, J., Zhang, M., Zhang, Y., Zeng, Y., Zhang, L., and Zhao, X., 2016. Anticoagulant and FGF/FGFR signal activating activities of the heparinoid propylene glycol alginate sodium sulfate and its oligosaccharides. Carbohydrate Polymers, 136: 641–648.
Zeng, Y., Yang, D., Qiu, P., Han, Z., Zeng, P., He, Y., Guo, Z., Xu, L., Cui, Y., Zhou, Z., Zhang, M., Hao, J., and Zhang, L., 2016. Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond-A review of 27 years clinical experiences in China. Clinical and Applied Thrombosis/Hemostasis, 22 (3): 222–229.
Zhang, Z., Yu, G., Zhao, X., Liu, H., Guan, H., Lawson, A. M., and Chai, W., 2006. Sequence analysis of alginate-derived oligosaccharides by negative-ion electrospray tandem mass spectrometry. Journal of the American Society for Mass Spectrometry, 17 (4): 621–630.
Acknowledgements
This research was supported by the National Natural Science Foundation of China (No. 91129706), NSFCShandong Joint Fund (No. U1406402), and Taishan Scholar Special Fund of Shandong Province in China (L. Z.).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zeng, X., Lan, Y., Zeng, P. et al. Polyguluronate sulfate, polymannuronate sulfate, and their oligosaccharides have antithrombin III- and heparin cofactor II-independent anticoagulant activity. J. Ocean Univ. China 16, 346–350 (2017). https://doi.org/10.1007/s11802-017-3205-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11802-017-3205-z